English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/125835
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer’s disease

AuthorsCuadrado-Tejedor, M.; Mederos, Sara; Perea, Gertrudis ; García-Osta, A.
KeywordsHistone deacetylase (HDAC)
Phosphodiesterase (PDE)
Alzheimer’s disease (AD)
Memory
Amyloid
Tau
Gene transcription
Issue Date8-Oct-2015
PublisherBioMed Central
CitationClinical Epigenetics 7(1): 108 (2015)
Abstract[Background] Given the implication of histone acetylation in memory processes, histone deacetylase inhibitors (HDACIs) have been postulated as potential modulators of cognitive impairment in Alzheimer’s disease (AD). However, dose-dependent side effects have been described in patients with the currently available broad-spectrum HDACIs, explaining why their therapeutic potential has not been realized for chronic diseases. Here, by simultaneously targeting two independent enzyme activities, histone deacetylase (HDAC) and phosphodiesterase-5 (PDE5), we propose a novel mode of inhibitory action that might increase the therapeutic specificity of HDACIs.
[Results] The combination of vorinostat, a pan-HDACI, and tadalafil, a PDE5 inhibitor, rescued the long-term potentiation impaired in slices from APP/PS1 mice. When administered in vivo, the combination of these drugs alleviated the cognitive deficits in AD mice, as well as the amyloid and tau pathology, and it reversed the reduced dendritic spine density on hippocampal neurons. Significantly, the combination of vorinostat and tadalafil was more effective than each drug alone, both against the symptoms and in terms of disease modification, and importantly, these effects persisted after a 4-week washout period.
[Conclusions] The results highlight the pharmacological potential of a combination of molecules that inhibit HDAC and PDE5 as a therapeutic approach for AD treatment.
Publisher version (URL)http://dx.doi.org/10.1186/s13148-015-0142-9
URIhttp://hdl.handle.net/10261/125835
DOI10.1186/s13148-015-0142-9
ISSN1868-7075
E-ISSN1868-7083
Appears in Collections:(IC) Artículos
Files in This Item:
File Description SizeFormat 
13148_2015_Article_142.pdf1,8 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.